Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Carmignac Gestion

Carmignac Gestion boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 182,507 shares of the biopharmaceutical company’s stock after buying an additional 65,936 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.5% of Carmignac Gestion’s holdings, making the stock its 18th largest position. Carmignac Gestion’s holdings in Regeneron Pharmaceuticals were worth $113,827,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. California State Teachers Retirement System increased its holdings in shares of Regeneron Pharmaceuticals by 63,274.2% in the 2nd quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company’s stock valued at $60,934,625,000 after acquiring an additional 97,569,482 shares during the last quarter. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $5,682,636,000. Dodge & Cox lifted its stake in Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock worth $3,547,791,000 after purchasing an additional 45,513 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Regeneron Pharmaceuticals by 4.4% in the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after purchasing an additional 106,861 shares in the last quarter. Finally, Nuveen LLC boosted its holdings in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,146 shares of company stock valued at $3,432,488 over the last ninety days. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $17.41 during trading hours on Tuesday, hitting $810.31. The stock had a trading volume of 556,467 shares, compared to its average volume of 836,365. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market capitalization of $83.43 billion, a PE ratio of 20.03, a PEG ratio of 1.62 and a beta of 0.20. The stock’s 50 day moving average is $745.94 and its 200 day moving average is $719.88. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the previous year, the company posted $12.81 EPS. The company’s quarterly revenue was up 16.7% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Harbor Mid Cap Value Fund’s Q2 2026 investor letter reportedly discusses the bullish potential of Regeneron, providing some support for the long-term investment case. Evaluating Bullish Potential in Regeneron Pharmaceuticals Stock
• Neutral Sentiment: Regeneron shares had gained about 8.1% over six months but lagged the S&P 500’s 13.6% return, prompting debate over whether the stock’s valuation and growth outlook remain attractive. Three Reasons to Avoid REGN
• Negative Sentiment: Pomerantz, Faruqi & Faruqi, Bernstein Liebhard, Robbins Geller, SBS Law and other firms are soliciting investors who purchased REGN shares between August 1, 2025, and May 15, 2026. Investors have until September 14, 2026, to seek appointment as lead plaintiff, increasing near-term legal overhang and investor attention. Pomerantz Investor Alert
• Negative Sentiment: The lawsuit follows what plaintiffs describe as surprising disclosures about the Phase III Fianlimab-Libtayo melanoma study. Investor notices allege that Regeneron’s statements about the trial were misleading before the shares declined from their class-period high. REGN Class-Action Deadline Alert

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. HSBC reduced their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Finally, Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Fourteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $800.36.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.